scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1085422047 |
P356 | DOI | 10.1007/S11060-017-2469-X |
P698 | PubMed publication ID | 28510787 |
P2093 | author name string | Minesh Mehta | |
Jeffrey Raizer | |||
Kenji Muro | |||
James Chandler | |||
Irene Helenowski | |||
Robert Levy | |||
Priya Kumthekar | |||
Maryanne Marymont | |||
Sean Grimm | |||
Katie McCarthy | |||
Leanne Fountas | |||
P2860 | cites work | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 |
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells | Q34128180 | ||
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma | Q34498352 | ||
Mechanisms of action of arsenic trioxide. | Q34525425 | ||
Radiotherapy and temozolomide for anaplastic astrocytic gliomas. | Q36163603 | ||
Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth | Q36545726 | ||
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies | Q36693019 | ||
Understanding the role of tumor stem cells in glioblastoma multiforme: a review article | Q37790294 | ||
Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models | Q37856463 | ||
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide | Q38390616 | ||
Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas | Q39766734 | ||
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide | Q40520929 | ||
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting | Q43068233 | ||
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies | Q43128991 | ||
Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas | Q48415956 | ||
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma | Q48605897 | ||
Bevacizumab for newly diagnosed glioblastoma | Q87922532 | ||
P433 | issue | 3 | |
P921 | main subject | phase II clinical trial | Q42824440 |
P304 | page(s) | 589-594 | |
P577 | publication date | 2017-05-16 | |
P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
P1476 | title | A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas | |
P478 | volume | 133 |
Q52646455 | A highlight on Sonic hedgehog pathway. |
Q57485029 | A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system |
Q64057935 | Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer |
Q93163558 | Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup |
Q52584360 | Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2. |
Q47435333 | Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation |
Q55456713 | Do Selected Blood Inflammatory Markers Combined with Radiological Features Predict Proliferation Index in Glioma Patients? |
Q61445010 | WZY-321, a novel evodiamine analog, inhibits glioma cell growth in an autophagy-associated manner |
Search more.